CD247 and neoplasm: Whilst the first-generation CARs comprise a CD3ζ signaling domain that mimics the T-cell receptor signaling pathway, facilitating low cytotoxicity and anti-tumor effectiveness, the second-generation CARs include both CD3ζ and co-stimulatory domain CD28, that enhances T cell proliferation (Tomasik et al., 2022).